first read beat bit mix perhap
ep guidanc maintain
view js results/guid bit mix headlin number suggest sale beat quarter mainli
attribut pharmaceut franchis pharma perform bit like tale two citiesj saw signific growth
sever new er product signific declin other due biosimilar/gener eros impact medicar part d/rebat impact
net/net still view top-lin perform posit think market may nit-pick ep beat done past
quarter sell business/asset record signific gain prompt beat reinvest gain back busi
futur quarter think like maintain full-year ep guidanc despit beat end could
disappoint lack higher full-year ep guidanc
litig particular focu stock took fairli modest context litig charg million
detail provid charg reflect note mainli attribut devic million consum
million busi pharma-rel expens million understand previous accru
litig liabilities/settl relat talc meet fa statement criteria estim loss accru
loss probabl reason estim expect litig liabil topic discuss today call rate
feel free reach question
sale beat report sale million ahead refinitiv consensu million estim
top-lin beat function better pharma sale orldw ide sale ere dow report basi
constant currenc basi organ basi orldw ide sale ere driven pharmaceut busi
partial off-set slow er grow th medic devic consum
ep beat adjust ep ere ahead street estim beat function higher
expect sale higher incom billion vs expect billion includ billion gain sale
asp busi adjust result sale busi inclus adjust number expect though
magnitud gain may bit includ may model note histor includ
gain sale businesses/asset adjust result view ed portfolio manag on-going part
busi strategi compani typic look reinvest gain
guidanc updat rais sale expect ep guidanc maintain despit beat
 ith top-lin beat perform year-to-d basi rais organ sale grow th guidanc year
 expect color call believ sale like come bit
favor yearw think like pharma
despit ep beat quarter maintain full-year adjust ep rang street current
 expect detail quarterli call today believ manag ill like indic plan reinvest gain
sale asp back busi support futur grow th initi
constant currenc sale grow th strong intern sale grow th off-set declin unit
state dow ow ing biosimilar/gener eros
oncolog continu best perform ith sale driven strong grow th darzalex imbruvica
off-set expect gener eros zytiga dow dow us velcad dow
immunolog sale ere strong grow th tremfya stelara off-set
continu biosimilar competit increas rebate/discount remicad
cardiovascular metabol dow reflect sale declin xarleto dow higher part utilization/reb
donut hole util legisl rebat chang invokana dow competit pressur safeti label updat
trend neurosci ere infecti diseas immunolog pulmonari hypertens
sale ere organ basi constant currenc basi sale ere dow mainli reflect sale
diabet asp/steril busi
orthoped sale ere hip ere knee ere dow cite competit pressur us trauma
spine dow expect hear addit commentari js take orthoped market believ
competit pressur continu gain share past sever quarter
surgeri dow inclus impact asp divestitur advanc surgeri hile gener surgeri
dow ith latter reflect temporari stapler recal impact
vision reflect grow th contact lenses/oth partial off-set declin surgic ith latter
impact us declin
intervent solut sale ere reflect continu strong grow th electrophysiolog
sale ere adjust operational/organ basi constant currenc basi sale ere
beauti continu drive overal perform ith sale reflect dr ci labo acquisit share gain
neutrogena aveeno ell ogx maui moistur geograph channel expans partial off-set roc nizor
over-the-counter sale came ere lighter consensu rise zarbe acquisit zyrtec share market gain strong
sale share grow th pediatr analges grow th tylenol ere partial off-set retail stock dynam
babi reflect easier comp due johnson us relaunch partial off-set declin aveeno babi due
channel shift
categori oral women dow wound /other dow
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target reflect blend averag compar analysi base appli
current year price-to-earnings multipl forw ard year earn sum-of-the-part analysi use pharma med tech consum peer
forw ard year price-to-earnings multipl dcf analysi
risk may imped achiev barclay research valuat price upsid risk thesi
moder impact drug price healthcar reform deploy balanc sheet find grow th asset better expect
clinic commerci success pipelin asset market rotat defens stock nside risk pressur
biosimilar remicade/zytiga pipelin failur slow ing medic devic util low er consum spend hile rotat
defens stock could exert dow nw ard pressur
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli pe multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit
could pressur earn grow th competit pressur particularli area knee competitor launch compet
robotic-assist system could impact grow th outlook sentiment tow ard stock time ultim receipt new
product approv could affect outlook risk includ signific chang reimburs potenti dilut associ
 ith acquisit product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur underw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
